Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Einstein-Extension: Rivaroxaban for Long-term Prevention of Recurrent VTE
NCT00439725Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 33
01
Overview
A Phase 3 trial of rivaroxaban in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), sponsored by Bayer. Started Feb 2007; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00439725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00439725.